Why Patients Are Asking
Primary care offices are fielding a question they rarely heard three years ago: can I just get the blood test?
The prompt is recent research. A study published in JAMA on July 14 and presented at the Alzheimer's Association International Conference followed roughly 2,700 cognitively unimpaired adults, average age 70, for an average of nearly five years and some for more than a decade. Among those with very high p-tau217 levels, the absolute risk of developing cognitive impairment was about 33 percent within five years and 78 percent within ten. Even in people with only slightly elevated levels, risk was 15 percent at five years and 45 percent at ten.
"Our findings provide some of the clearest evidence yet that elevated p-tau217 levels may help detect dementia risk years earlier, even in adults with no noticeable memory or thinking problems," said lead author Rachel F. Buckley, PhD, of Mass General Brigham and Harvard Medical School.
Here is the part that answers the question in the headline for most readers. Blood tests for Alzheimer's pathology are cleared by the FDA for adults who already have signs or symptoms of cognitive decline. Routine presymptomatic testing in people without symptoms is not a standard approved indication. A healthy 62-year-old who calls and asks for the test is asking for something outside the cleared use, which does not make it impossible but does change the conversation.
What a Positive Result Actually Means
A positive result says something specific and narrower than most people assume.
An elevated p-tau217 level indicates a higher likelihood that Alzheimer's-related changes, including amyloid pathology, are present in the brain. It is evidence of biology. It is not, by itself, a diagnosis of Alzheimer's dementia.
That distinction is not academic. Amyloid pathology can be present in people who never develop dementia in their lifetime. A person with memory complaints and a positive result may have Alzheimer's disease driving those symptoms, or may have depression, sleep apnea, thyroid dysfunction, medication side effects, or vascular disease driving them while the amyloid sits in the background. A clinician still has to assess daily function, mood, sleep, medications, and other causes.
Accuracy is good and not perfect, and it varies by setting. In a study of 1,767 people with cognitive symptoms across European cohorts using a fully automated assay, plasma p-tau217 detected Alzheimer's pathology with accuracy of 89 to 91 percent in specialist care, where positive predictive values ran 89 to 95 percent. In the primary care cohort, accuracy was 85 percent, with a positive predictive value of 82 percent and a negative predictive value of 88 percent.
An 82 percent positive predictive value means that among primary care patients with symptoms who test positive, roughly one in five does not have the pathology the test is looking for.
What the Test Cannot Tell You
Several limits are worth knowing before rather than after.
It cannot tell you when symptoms will begin, how fast they will progress, or whether they will begin at all. The JAMA figures are population risks across a group, not a personal timeline.
It can be influenced by things that have nothing to do with the brain. Reduced kidney function can raise p-tau217 levels on its own, which is one reason results are read alongside the rest of a person's health rather than in isolation.
It is not a genetic test. It measures a protein in blood and says nothing about whether someone carries an Alzheimer's-associated gene variant. Predictive genetic testing is a separate decision with its own counseling.
Not every available test is the same product. Some are FDA-cleared in vitro diagnostics, while others are laboratory-developed tests that have not been evaluated or cleared by the FDA. Results from different assays are not directly comparable, and switching labs mid-course can make numbers misleading.
What Would Change If You Knew
This is the question that should decide whether to test, and it deserves an honest answer rather than an inspirational one.
For a person with cognitive symptoms, the answer can be substantial. A result can distinguish Alzheimer's from treatable causes, which changes management immediately. It can establish eligibility for anti-amyloid therapy, which requires confirmed amyloid pathology and a diagnosis at the mild cognitive impairment or mild dementia stage. It can shorten a diagnostic odyssey that historically required PET imaging or a spinal tap.
For a person without symptoms, the answer is thinner. No approved treatment exists for presymptomatic Alzheimer's pathology. The interventions available to someone with an elevated result, meaning blood pressure control, physical activity, hearing correction, sleep treatment and metabolic risk management, are the same ones recommended to any older adult. A positive result may increase motivation, and it may also produce years of anxiety with no treatment to act on.
Buckley framed the near-term value in research terms, noting these tests could be used to recruit participants for prevention trials, and that in the future, when treatments are approved early in the disease process, they could guide monitoring, treatment decisions and counseling.
There are practical consequences too. A biomarker result becomes part of the medical record. Federal genetic nondiscrimination protections apply to genetic information and do not extend to all biomarker results, and life, long-term care and disability insurance sit outside those protections entirely.
Questions to Settle Before the Blood Draw
A short conversation before testing prevents most of the difficulty that follows a result.
Ask why the test is being ordered and what decision it would inform. Ask which specific test is being used and whether it is FDA-cleared or a laboratory-developed test. Ask what the plan is for a positive result, a negative result, and a borderline result, since values near a cutoff are common and sometimes warrant confirmation with cerebrospinal fluid testing or imaging.
Ask about cost and coverage before the draw rather than after. Ask who will deliver and explain the result, and whether that will happen in a scheduled visit rather than through a patient portal message.
Decide in advance whom you want to tell. That decision is easier to make before a number exists than after.
Anyone with new or worsening memory, language, navigation, or judgment problems should seek evaluation regardless of interest in biomarker testing, because reversible causes are common and treatable. Sudden confusion, sudden weakness, or sudden speech difficulty is a medical emergency and requires 911.
MedicalDaily will report changes to FDA clearance scope, new clinical guidance on biomarker use in primary care, and results from prevention trials using biomarker-based risk stratification.
Frequently Asked Questions
Can I ask my doctor for an Alzheimer's blood test? You can ask. The tests are FDA-cleared for adults who already have cognitive symptoms. Testing people without symptoms is not a standard approved indication.
Does a positive result mean I have Alzheimer's? No. It indicates a higher likelihood that Alzheimer's-related brain changes are present. Diagnosis requires clinical assessment alongside the result.
How accurate is it? In one large study, accuracy was 89 to 91 percent in specialist settings and 85 percent in primary care, where the positive predictive value was 82 percent.
Can anything else raise the level? Yes. Reduced kidney function can elevate p-tau217 independently, which is one reason results are interpreted alongside overall health.
Is this a genetic test? No. It measures a blood protein and does not identify gene variants. Genetic testing is a separate decision.
What could I do with a positive result? If you have symptoms, it can clarify the cause and establish eligibility for anti-amyloid treatment. Without symptoms, no approved treatment currently exists for the pathology alone.
What should I ask before testing? What decision the result would inform, which test is being used, the plan for each possible result, the cost, and who will explain the result to you.
